CanVECTOR in the News

Latest CanVECTOR News
« Back to listings

Announcing the next CanVECTOR Co-Lead of the Clinical Trials & Shared Platforms platform: Dr. Leslie Skeith

06-23-2022

The Network is pleased to announce that following a Network-wide Call for Nominations and vote, Dr. Leslie Skeith has been elected as the incoming CanVECTOR Co-Lead of the Clinical Trials & Shared Platforms platform as of August 1st, 2022. Dr. Skeith will replace Dr. Grégoire Le Gal -  the network's incoming Co-Director - as Co-Lead of the platform to work alongside platform Co-Lead Dr. Deborah Siegal. 

Dr. Leslie Skeith is an Associate Professor in the Division of Hematology & Hematological Malignancies, Department of Medicine at the University of Calgary. Dr. Skeith has been an exemplary researcher and leader within CanVECTOR since its inception, as a Fellowship Award winner, recipient of the 2016 Pilot Trials Funding Competition award, principal investigator and co-investigator on several Network-supported studies, and as a Co-Lead of the Training, Mentoring, and Early Career Development platform.

As CanVECTOR's success relies upon outstanding leadership and a commitment to ensuring the network continually evolves to meet the needs of its members, we are thrilled to welcome Dr. Skeith in this new role to help guide the platform forward.

CanVECTOR sincerely thanks all applicants for putting their names forward for this position. Our success and growth as a network wouldn't be possible without members' interest and involvement in all aspects of the network.


Important Note: Open Co-Lead Position, Training, Mentoring, & Early Career Development platform
 
The Co-Lead position of the Training, Mentoring, & Early Career Development platform will be vacant as of August 1st, 2022. CanVECTOR will hold an election to fill this position.  Stay tuned for complete details.

Should you have any questions about this process, please email info@canvector.ca.


Thank you

Agnes Lee, MD, MSc, FRCPC
CanVECTOR SSC Elections Chair

Comments

There are currently no comments.

Log in to post a comment.